In the last trading session, 2.23 million Sangamo Therapeutics Inc (NASDAQ:SGMO) shares changed hands as the company’s beta touched 1.24. With the company’s per share price at $0.54 changed hands at $0.0 or 0.07% during last session, the market valuation stood at $132.84M. SGMO’s last price was a discount, traded about -488.89% off its 52-week high of $3.18. The share price had its 52-week low at $0.30, which suggests the last value was 44.44% up since then. When we look at Sangamo Therapeutics Inc’s average trading volume, we note the 10-day average is 6.89 million shares, with the 3-month average coming to 7.13 million.
Analysts gave the Sangamo Therapeutics Inc (SGMO) stock a consensus recommendation rating of Hold, calculated at a mean rating of 1.71. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended SGMO as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight.
Sangamo Therapeutics Inc (NASDAQ:SGMO) trade information
Instantly SGMO was in green as seen at the end of in last trading. With action 25.30%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 27.85%, with the 5-day performance at 25.30% in the green. However, in the 30-day time frame, Sangamo Therapeutics Inc (NASDAQ:SGMO) is 18.27% up. Looking at the short shares, we see there were 25.67 million shares sold at short interest cover period of 5.16 days.
The consensus price target for the stock as assigned by Wall Street analysts is 4, meaning bulls need an upside of 86.5% from its current market value. According to analyst projections, SGMO’s forecast low is 2 with 19 as the target high. To hit the forecast high, the stock’s price needs a -3418.52% plunge from its current level, while the stock would need to soar -270.37% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 10.57%. The 2025 estimates are for Sangamo Therapeutics Inc earnings to increase by 25.18%, but the outlook for the next 5-year period is at 20.67% per year.
SGMO Dividends
Sangamo Therapeutics Inc is expected to release its next quarterly earnings report on 2025-May-12.
Sangamo Therapeutics Inc (NASDAQ:SGMO)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 2.84% of Sangamo Therapeutics Inc shares while 22.34% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 23.00%. There are 22.34% institutions holding the Sangamo Therapeutics Inc stock share, with WASATCH ADVISORS LP the top institutional holder. As of 2024-06-30, the company held 9.8509% of the shares, roughly 20.09 million SGMO shares worth $7.2 million.
ARMISTICE CAPITAL, LLC holds the second largest percentage of outstanding shares, with 6.894% or 14.06 million shares worth $5.04 million as of 2024-06-30.
